IRulya Therapeutics Inc.
IRLAIRulya Therapeutics Inc. in brief
IRulya Therapeutics Inc. is a listed company in the Biotechnology industry, based in California, USA. Its market value was $343 M on 30 October 2026, which makes it the 14,231st largest listed company in the world and the 2,786th largest in the USA on this site. It employs about 55 people. Its shares trade under the symbol IRLA (Nasdaq).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About IRulya Therapeutics Inc.
Cortexyme is a Clinical Stage Biopharmaceutical company. It is a pioneering upstream therapeutic approaches designed to improve the lives of patients diagnosed and other degenerative diseases. The company is targeting a specific, infectious pathogen found in the brain of Alzheimer’s patients that causes neurodegeneration and other pathology in animal models. The headquarters is in USA.
IRulya Therapeutics Inc. timeline
- 2016
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 2019
- 🔔Initial public offering as Cortexyme, Inc.Final prospectus filed with the SEC on 9 May 2019; shares registered for exchange trading on 1 May 2019.
- 2022
- ✎Renamed Quince Therapeutics, Inc.Formerly Cortexyme, Inc..
- 2026
- ✎Renamed IRulya Therapeutics Inc.Formerly Quince Therapeutics, Inc..
Events of IRulya Therapeutics Inc. from SEC EDGAR. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in USA: #1,776 (Jan 2020) · #2,361 (Jan 2021) · #3,262 (Jan 2022) · #2,873 (Oct 2026) · #2,790 (Oct 2026)
Key ratios
- P/E ratio
- n/m (loss)
- Price / sales
- —
- Price / book
- —
- Free cash flow yield
- -12.2%
- Net margin
- —
- Operating margin
- —
- Return on equity
- —
- Liabilities / assets
- 138.2%
- Net debt
- $-6M
- Profit per employee
- $-1.5 M
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | — | — | $-58M | $-84M | — |
| Dec 2024 | — | — | $-57M | $-57M | — |
| Dec 2023 | — | — | $-35M | $-31M | — |
| Dec 2022 | — | — | $-52M | $-52M | — |
| Dec 2021 | — | — | $-90M | $-90M | — |
| Dec 2020 | — | — | $-79M | $-77M | — |
| Dec 2019 | — | — | $-39M | $-37M | — |
| Dec 2018 | — | — | $-12M | $-12M | — |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2025 | $-41M | $0M | $-42M | $-1.68 | — |
| Dec 2024 | $-32M | $0M | $-32M | $-1.31 | — |
| Dec 2023 | $-18M | $0M | $-18M | $-0.84 | — |
| Dec 2022 | $-44M | $0M | $-44M | $-1.54 | — |
| Dec 2021 | $-63M | $0M | $-63M | $-3.03 | — |
| Dec 2020 | $-51M | $0M | $-51M | $-2.63 | — |
| Dec 2019 | $-33M | $0M | $-33M | $-1.94 | — |
| Dec 2018 | $-12M | $0M | $-12M | $-3.71 | — |
Quarterly results
Latest quarter to Sep 2026: revenue —, net income $-28M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Jun 2026.
SEC filings
- Oct 19, 20268-KCurrent reportRegulation FD disclosure
- Oct 9, 20268-KCurrent reportDirectors or officers changed · Bylaws amended · Regulation FD disclosure · Other events
- Oct 6, 20268-KCurrent reportDirectors or officers changed · Bylaws amended · Shareholder vote
- Oct 2, 20268-KCurrent reportDirectors or officers changed
- Sep 14, 20268-KCurrent reportAcquisition or disposal completed · Directors or officers changed
- Sep 4, 20268-KCurrent reportListing notice
- Aug 27, 20268-KCurrent reportDirectors or officers changed
- Aug 25, 2026DEF 14AProxy statement
- Aug 17, 20268-KCurrent reportOther events
- Aug 14, 202610-QQuarterly report · period to Jun 2026
- Aug 14, 20268-KCurrent reportResults of operations
- Jul 31, 20268-KCurrent reportDirectors or officers changed
Official filings of IRulya Therapeutics Inc. with the US Securities and Exchange Commission.
Annual results
- Revenue
- —
- Operating income
- $-58 M
- Net income
- $-84 M
For year ending December-2025 · source: SEC filing
Balance sheet
- Total assets
- $94 M
- Total liabilities
- $129 M
- Total equity
- $-36 M
As of December-2025
Top 33 institutional investors in IRulya Therapeutics Inc.#
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 1 | Janus Henderson Group Ltd. | 1,714,957 | — | 15.82% | $53 M | Nov 16, 2026 |
| 2 | Ikarian Capital, LLC | 95,652 | +23,401 (+32.39%) | 0.88% | $3 M | Nov 16, 2026 |
| 3 | Squadron Capital Management LLC | 90,000 | +49,625 (+122.91%) | 0.83% | $3 M | Nov 16, 2026 |
| 4 | Millennium Management LLC | 72,254 | +1,475 (+2.08%) | 0.67% | $2 M | Nov 16, 2026 |
| 5 | Balyasny Asset Management L.P. | 69,970 | +3 (0.00%) | 0.65% | $2 M | Nov 16, 2026 |
| 6 | Acuta Capital Partners, LLC | 52,918 | New | 0.49% | $2 M | Nov 16, 2026 |
| 7 | Birchview Capital, LP | 40,601 | New | 0.37% | $1 M | Nov 13, 2026 |
| 8 | Boothbay Fund Management, LLC | 21,291 | +7,380 (+53.05%) | 0.20% | $1 M | Nov 16, 2026 |
| 9 | Jane Street Group, LLC | 20,156 | +7,514 (+59.44%) | 0.19% | $1 M | Nov 12, 2026 |
| 10 | Seven Fleet Capital Management LP | 11,989 | New | 0.11% | $0 M | Nov 16, 2026 |
| 11 | Geode Capital Management, LLC | 9,741 | New | 0.09% | $0 M | Nov 6, 2026 |
| 12 | Vanguard Capital Management LLC | 9,216 | -2,828 (-23.48%) | 0.09% | $0 M | Nov 13, 2026 |
| 13 | Cormorant Asset Management, LP | 5,498 | 0 (0.00%) | 0.05% | $0 M | Nov 16, 2026 |
| 14 | Vanguard Fiduciary Trust Co | 5,372 | +1,758 (+48.64%) | 0.05% | $0 M | Nov 13, 2026 |
| 15 | BlackRock, Inc. | 1,689 | -13 (-0.76%) | 0.02% | $0 M | Nov 13, 2026 |
| 16 | Morgan Stanley | 794 | -3,290 (-80.56%) | 0.01% | $0 M | Nov 13, 2026 |
| 17 | Jpmorgan Chase & Co | 792 | +790 (+39500.00%) | 0.01% | $0 M | Nov 12, 2026 |
| 18 | Wells Fargo & Company/mn | 314 | +304 (+3040.00%) | 0.00% | $0 M | Nov 16, 2026 |
| 19 | Group One Trading LLC | 234 | New | 0.00% | $0 M | Nov 10, 2026 |
| 20 | Gen-Wealth Partners Inc | 166 | +1 (+0.61%) | 0.00% | $0 M | Nov 4, 2026 |
| 21 | Fortitude Family Office, LLC | 41 | +1 (+2.50%) | 0.00% | $0 M | Oct 14, 2026 |
| 22 | BFC Planning, Inc. | 15 | +1 (+7.14%) | 0.00% | $0 M | Nov 13, 2026 |
| 23 | BNP Paribas Financial Markets | 9 | New | 0.00% | $0 M | Nov 12, 2026 |
| 24 | Allworth Financial LP | 8 | 0 (0.00%) | 0.00% | $0 M | Nov 17, 2026 |
| 25 | Parallel Advisors, LLC | 6 | +3 (+100.00%) | 0.00% | $0 M | Nov 3, 2026 |
Show all 33: investors 26 to 33
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 26 | UBS Group AG | 4 | -4,726 (-99.92%) | 0.00% | $0 M | Nov 10, 2026 |
| 27 | Osaic Holdings, Inc. | 2 | New | 0.00% | $0 M | Nov 12, 2026 |
| 28 | JDM Financial Group LLC | 2 | +1 (+100.00%) | 0.00% | $0 M | Nov 17, 2026 |
| 29 | FMR LLC | 1 | New | 0.00% | $0 M | Nov 10, 2026 |
| 30 | Jones Financial Companies Lllp | 1 | New | 0.00% | $0 M | Nov 13, 2026 |
| 31 | Royal Bank Of Canada | 1 | 0 (0.00%) | 0.00% | $0 M | Nov 16, 2026 |
| 32 | Westside Investment Management, Inc. | 1 | 0 (0.00%) | 0.00% | $0 M | Nov 2, 2026 |
| 33 | Steward Partners Investment Advisory, LLC | 1 | 0 (0.00%) | 0.00% | $0 M | Nov 13, 2026 |
Mutual funds holding IRulya Therapeutics Inc.#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc. | 12,044 | $0 M | 1.2% | <0.01% | new | Jun 30, 2026 |
Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jun 30, 2026. The 1 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.
Insider trading at IRulya Therapeutics Inc.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | John MilitelloChief Financial Officer | Grant or award | +80,000 | — | — | 80,000 | Form 4 |
| filed | Luca BenattiDirector | Sell | -50,000 | $3.470 | $174 K | 39,179 | Form 4 |
| filed | Dirk ThyeCEO and CMO, Director | Gift | -739,885 | — | — | 255,000 | Form 4 |
| filed | Dirk ThyeCEO and CMO, Director | Giftindirect | +739,885 | — | — | 739,885 | Form 4 |
| filed | Brendan HannahCBO, COO & CCO | Option exercise | +2,271 | $0.550 | $1 K | 336,547 | Form 4 |
| filed | Brendan HannahCBO, COO & CCO | Option exercise | +25,280 | $0.940 | $24 K | 361,827 | Form 4 |
| filed | Charles S. RyanPresident | Grant or award | +7,548 | $1.200 | $9 K | 130,009 | Form 4 |
| filed | Brendan HannahCBO, COO & CCO | Grant or award | +37,736 | $1.200 | $45 K | 334,276 | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: IRulya Therapeutics Inc.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Stock splits: 1-for-2.72 reverse split
Fails to deliver
- : 969 shares at $31.62
- : 236 shares at $31.38
- : 660 shares at $33.08
- : 302 shares at $32.83
- : 1,844 shares at $34.68
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
IRulya Therapeutics Inc. scorecard#
Passes 1 of the 12 checks that could be worked out: strongest in financial health (1 of 3), weakest in valuation (0 of 4). Fiscal year 2025; market cap of Oct 30, 2026.
Valuation0 of 4
- ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
- ✗Price to book below its peers' medianNo price to bookShareholders' equity is negative.
- –Price to sales below its peers' medianNo Price to sales on file.
- ✗Free cash flow yield above 5%-12.2%Free cash flow is -12.2% of the market value.
- ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
- –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
Growth0 of 2
- –Revenue grew in the newest yearRevenue of the year before is not on file.
- –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
- –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
- ✗Earnings per share grew in the newest year-1.68 vs -1.31Diluted EPS -1.68 in fiscal 2025 against -1.31 the year before (report's currency).
- ✗Net income higher than five years earlier-$84 M-$84 M in fiscal 2025 against -$77 M in 2020.
- –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
Profitability0 of 2
- ✗Profitable in the newest year-$84 MNet income -$84 M in fiscal 2025.
- ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
- –Operating margin above its peers' medianNo operating margin on file.
- –Return on equity above 15%No return on equity (equity missing or negative).
- –Return on invested capital above 10%No return on invested capital on file.
- –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
Financial health1 of 3
- ✗Short-term assets cover short-term liabilities0.5×Current ratio 0.53 at the end of fiscal 2025.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- ✓Net debt below three years of EBITDANet cashMore cash than debt: net cash of $6 M at the end of fiscal 2025.
- –Operating income covers interest five timesInterest expense is not on file.
- ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
- –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
Shareholder returns0 of 1
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- ✗Share count up no more than 2% in a year15.8%Diluted shares up 15.8% in fiscal 2025.
- –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
- –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.
Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
IRulya Therapeutics Inc.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Dec 31, 2025 | FY 2024to Dec 31, 2024 | FY 2023to Dec 31, 2023 | FY 2022to Dec 31, 2022 | FY 2021to Dec 31, 2021 | FY 2020to Dec 31, 2020 | FY 2019to Dec 31, 2019 | FY 2018to Dec 31, 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||
| Research and development | 35+90.3%— | 19+96.8%— | 9.4−62.5%— | 25−58.6%— | 61−0.8%— | 61+103%— | 30+200%— | 10—— | |
| General and administrative | 15−14.4%— | 18−0.6%— | 18−32.0%— | 26−11.9%— | 30+67.9%— | 18+96.4%— | 9.0+340%— | 2.0—— | |
| Operating expenses | 58+1.4%— | 57+65.5%— | 35−33.4%— | 52−42.4%— | 90+14.5%— | 79+101%— | 39+223%— | 12—— | |
| Operating income | −58—— | −57—— | −35—— | −52—— | −90—— | −79—— | −39—— | −12—— | |
| Interest and finance income | 1.2−57.5%— | 2.9−15.8%— | 3.5+226%— | 1.1+72.3%— | 0.6−69.7%— | 2.0−6.6%— | 2.2+171%— | 0.8—— | |
| Interest expense and finance costs | — | — | — | — | — | — | — | 1.0—— | |
| Other non-operating income (expense) | 0.5—— | −0.7—— | −0.1—— | −1.0—— | −0.2—— | 0—— | 0—— | — | |
| Income before tax | −81—— | −57—— | −32—— | −52—— | −90—— | −77—— | −37—— | — | |
| Income tax | 3.2+3594%— | 0.1—— | −0.2r0.2—— | −0.3—— | 0—— | 0—— | 0—— | 0—— | |
| Net income including minority interests | — | −57—— | −31—— | −52—— | −90—— | −77—— | −37—— | −12—— | |
| Net income attributable to shareholders | −84—— | −57—— | −31—— | −52—— | −90—— | −77—— | −37—— | −12—— | |
| Earnings per share, basic | -1.68—— | -1.31—— | -0.84—— | -1.54—— | -3.03—— | -2.63—— | -1.94—— | -3.71—— | |
| Earnings per share, diluted | -1.68—— | -1.31—— | -0.84—— | -1.54—— | -3.03—— | -2.63—— | -1.94—— | -3.71—— | |
| Shares, weighted average (basic) | 50+15.8%— | 43+16.2%— | 37+11.2%— | 33+12.7%— | 30—— | — | — | — | |
| Shares, weighted average (diluted) | 50+15.8%— | 43+16.2%— | 37+11.2%— | 33+12.7%— | 30+1.9%— | 29+53.3%— | 19+466%— | 3.4—— | |
| Balance sheet | |||||||||
| Cash and cash equivalents | 5.8−6.5%6.2% | 6.2−70.1%5.4% | 21−48.9%12.4% | 41+37.8%39.1% | 29−55.9%22.1% | 67+30.5%35.3% | 51+106%41.2% | 25—34.1% | |
| Short-term investments | 12−65.5%12.8% | 35−36.3%30.2% | 54+19.1%32.3% | 46+23.0%43.9% | 37−44.6%27.8% | 67+37.7%35.4% | 49+3.9%39.1% | 47—64.3% | |
| Receivables | — | — | — | 0—0.0% | — | — | — | — | |
| Other current assets | 0.1−35.7%0.1% | 0.1+3.7%0.1% | 0.1−70.7%0.0% | 0.3−24.8%0.3% | 0.4−47.1%0.3% | 0.7+0.9%0.4% | 0.7+912%0.6% | 0.1—0.1% | |
| Current assets | 23−48.0%24.5% | 44−43.1%38.5% | 77−17.4%46.1% | 94−16.1%90.2% | 112−19.0%83.8% | 138+30.0%72.8% | 106+46.1%85.3% | 73—99.6% | |
| Property, plant and equipment | 0.6+88.9%0.6% | 0.3+34.6%0.3% | 0.2−40.5%0.1% | 0.4+49.4%0.4% | 0.3−38.4%0.2% | 0.4−39.8%0.2% | 0.7+151%0.6% | 0.3—0.4% | |
| Right-of-use (leased) assets | 0.5−9.0%0.5% | 0.5+29.4%0.4% | 0.4+32.3%0.2% | 0.3−75.0%0.3% | 1.2+72.8%0.9% | 0.7+7.8%0.4% | 0.6—0.5% | — | |
| Goodwill | — | 0−100%0.0% | 18—10.5% | 0—0.0% | 0—0.0% | — | — | — | |
| Other intangible assets | 68+12.9%72.5% | 60−5.7%52.5% | 64+979%37.9% | 5.9—5.7% | 0—0.0% | — | — | — | |
| Investments in associates | 0.10.0%0.1% | 0.10.0%0.1% | 0.1—0.0% | — | — | — | — | — | |
| Total assets | 94−18.3%100% | 114−31.8%100% | 168+61.6%100% | 104−22.0%100% | 133−29.7%100% | 189+52.3%100% | 124+70.7%100% | 73—100% | |
| Accounts payable | 2.2−23.4%2.4% | 2.9+42.8%2.5% | 2.0+257%1.2% | 0.6−88.4%0.5% | 4.9+38.1%3.7% | 3.6+15.6%1.9% | 3.1+521%2.5% | 0.5—0.7% | |
| Debt due within a year | 18—19.3% | 0—0.0% | — | — | — | — | — | — | |
| Current liabilities | 43+494%46.2% | 7.3−24.0%6.4% | 9.6+212%5.7% | 3.1−78.4%3.0% | 14−16.3%10.7% | 17+91.1%9.0% | 8.9+510%7.1% | 1.5—2.0% | |
| Lease liabilities (non-current) | 0.3−16.2%0.4% | 0.4+22.7%0.3% | 0.3—0.2% | 0−100%0.0% | 0.4+102%0.3% | 0.2—0.1% | — | — | |
| Total liabilities | 129+53.2%138% | 84+1.8%73.7% | 83+2397%49.3% | 3.3−77.3%3.2% | 15−14.9%11.0% | 17+93.5%9.1% | 8.9+510%7.1% | 1.5—2.0% | |
| Retained earnings | −460—−492% | −376—−329% | −320—−190% | −288—−277% | −237—−178% | −147—−77.4% | −70—−56.1% | −33—−45.0% | |
| Shareholders' equity | −36−218%−38.2% | 30−64.6%26.3% | 85−15.4%50.7% | 101−15.2%96.8% | 119−31.2%89.0% | 172+49.2%90.9% | 115—92.9% | −33—−44.8% | |
| Total liabilities and equity | 94−18.3%100% | 114−31.8%100% | 168+61.6%100% | 104−22.0%100% | 133−29.7%100% | 189+52.3%100% | 124+70.7%100% | 73—100% | |
| Shares outstanding | 0.3r56−99.4%— | 44+2.4%— | 43+18.9%— | 36+20.2%— | 30+1.8%— | 30+10.0%— | 27+687%— | 3.4—— | |
| Cash-flow statement | |||||||||
| Depreciation and amortization | 0.1−23.7%— | 0.2−42.2%— | 0.3+57.8%— | 0.2−40.7%— | 0.3+3.6%— | 0.3+76.6%— | 0.2+269%— | 0.1—— | |
| Share-based compensation | 5.1+7.6%— | 4.7−9.1%— | 5.2−68.6%— | 17−44.3%— | 30+106%— | 14+604%— | 2.1+1226%— | 0.2—— | |
| Cash from operating activities | −41—— | −32—— | −18—— | −44—— | −63—— | −51—— | −33—— | −12—— | |
| Capital expenditure | −0.4—— | −0.3—— | −0.2—— | −0.1—— | −0.2—— | −0.1—— | −0.1—— | −0.2—— | |
| Cash from investing activities | 23+6.0%— | 22—— | −5.8−132%— | 18−69.5%— | 59—— | −52—— | −18—— | −47—— | |
| Shares issued | — | — | 0−100%— | 0.6—— | 0—— | — | — | — | |
| Cash from financing activities | 18—— | −4.8−3439%— | 0.1−79.8%— | 0.7−89.6%— | 6.8−94.3%— | 119+53.7%— | 77+1.9%— | 76—— | |
| Exchange-rate effect on cash | −0.1−149%— | 0.2+189%— | 0.1−56.5%— | 0.2+235%— | 0.1—— | 0—— | 0—— | — | |
| Change in cash | −0.4—— | −15—— | −24—— | −25−972%— | 2.9−81.6%— | 16−40.7%— | 26—— | — | |
| Report | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Sep 30, 2026 | Q3 FY2026to Sep 30, 2026 | Q2 FY2026to Jun 30, 2026 | Q1 FY2026to Mar 31, 2026 | Q4 FY2025to Dec 31, 2025 | Q3 FY2025to Sep 30, 2025 | Q2 FY2025to Jun 30, 2025 | Q1 FY2025to Mar 31, 2025 | Q4 FY2024to Dec 31, 2024 | Q3 FY2024to Sep 30, 2024 | Q2 FY2024to Jun 30, 2024 | Q1 FY2024to Mar 31, 2024 | Q4 FY2023to Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||||||
| Research and development | 31+7.5%— | 5.9−27.6%— | 5.5−16.7%— | 6.8−16.0%— | 13*+116%— | 8.1+64.4%— | 6.6+58.0%— | 8.1+120%— | 5.8*+69.6%— | 4.9—— | 4.1—— | 3.7—— | 3.4*—— | |
| General and administrative | 34+114%— | 9.0+175%— | 17+397%— | 4.3−10.9%— | 3.6*−15.1%— | 3.3−9.6%— | 3.3−28.8%— | 4.8−3.7%— | 4.3*−12.7%— | 3.6—— | 4.7—— | 5.0—— | 4.9*—— | |
| Operating expenses | 127+150%— | 13−2.1%— | 80+665%— | 15−1.8%— | 19*+61.1%— | 13+129%— | 10−63.0%— | 15+32.4%— | 12*+21.1%— | 5.9—— | 28—— | 11—— | 9.9*—— | |
| Operating income | −127—— | −13—— | −80—— | −15—— | −19*—— | −13—— | −10—— | −15—— | −12*—— | −5.9—— | −28—— | −11—— | −9.9*—— | |
| Interest and finance income | 2.0+28.5%— | 1.0+241%— | 0.6+87.8%— | 0.2−60.6%— | 0.2*−57.6%— | 0.3−56.1%— | 0.3−62.2%— | 0.4−54.2%— | 0.5*−47.1%— | 0.7—— | 0.8—— | 0.9—— | 1.0*—— | |
| Other non-operating income (expense) | 0.9—— | −1.6—— | 0.2—— | 1.7—— | 0.7*—— | −0.1−139%— | −0.0−132%— | −0.1—— | −0.5*−229%— | 0.2—— | 0.1—— | −0.4—— | 0.4*—— | |
| Income before tax | — | — | — | — | — | — | — | −15—— | — | — | — | −11—— | — | |
| Income tax | −2.4−3327%— | −0.3—— | 0.1+11.9%— | −5.3−11460%— | 3.1*+44843%— | −0.0−454%— | 0.1+86.1%— | 0.0+51.6%— | 0.0*−86.3%— | 0.0—— | 0.0—— | 0.0—— | 0.1r0.4*—— | |
| Net income including minority interests | — | — | — | — | — | — | — | — | −12*—— | −5.5*—— | −28*—— | −11—— | −8.9*—— | |
| Net income attributable to shareholders | −107—— | −28—— | −75—— | 36—— | −39*—— | −13—— | −16—— | −15—— | −12*—— | −5.5—— | −28—— | −11—— | −8.9*—— | |
| Earnings per share, basic | — | -2.31—— | -12.31—— | 3.60—— | — | -49.83r-0.25—— | -68.75r-0.34—— | -3.42r-0.34—— | — | -0.13—— | -0.64—— | -0.26—— | — | |
| Earnings per share, diluted | — | -2.31—— | -12.31—— | 2.88—— | — | -49.83r-0.25—— | -68.75r-0.34—— | -3.42r-0.34—— | — | -0.13—— | -0.64—— | -0.26—— | — | |
| Shares, weighted average (basic) | 12+4350%— | 12+4350%— | 6.1+2527%— | 9.1+108%— | — | 0.3r54−99.4%— | 0.2r47−99.5%— | 4.4r44−89.8%— | — | 43—— | 43—— | 43—— | — | |
| Shares, weighted average (diluted) | 12+4350%— | 12+4350%— | 6.1+2527%— | 9.2+109%— | — | 0.3r54−99.4%— | 0.2r47−99.5%— | 4.4r44−89.8%— | — | 43—— | 43—— | 43—— | — | |
| Balance sheet | ||||||||||||||
| Cash and cash equivalents | 40—37.4% | 40+517%37.4% | 116+589%93.5% | 18+134%68.2% | 5.8−6.5%6.2% | 6.5+141%5.9% | 17+113%14.4% | 7.8−64.4%7.3% | 6.2−70.1%5.4% | 2.7—2.1% | 7.9—5.9% | 22—13.7% | 21—12.4% | |
| Short-term investments | 65—61.4% | 65—61.4% | 0—0.0% | 0—0.0% | 12−65.5%12.8% | — | — | — | 35−36.3%30.2% | 45—35.7% | 52—38.2% | 46—28.9% | 54—32.3% | |
| Other current assets | 0.1—0.1% | 0.1−32.3%0.1% | 0.4+615%0.3% | 0.0−25.0%0.1% | 0.1−35.7%0.1% | 0.1+74.5%0.1% | 0.1−30.4%0.0% | 0.0−33.3%0.0% | 0.1+3.7%0.1% | 0.1—0.0% | 0.1—0.1% | 0.0—0.0% | 0.1—0.0% | |
| Current assets | 106—99.8% | 106+264%99.8% | 123+230%99.5% | 26−24.4%96.1% | 23−48.0%24.5% | 29−43.5%26.6% | 37−41.1%31.9% | 34−52.0%31.6% | 44−43.1%38.5% | 52—40.9% | 63—47.1% | 70—44.2% | 77—46.1% | |
| Property, plant and equipment | 0.1—0.1% | 0.1−88.8%0.1% | 0.5−11.7%0.4% | 0.6+22.8%2.1% | 0.6+88.9%0.6% | 0.6+196%0.6% | 0.6+133%0.5% | 0.4+91.5%0.4% | 0.3+34.6%0.3% | 0.2—0.2% | 0.2—0.2% | 0.2—0.1% | 0.2—0.1% | |
| Right-of-use (leased) assets | 0—0.0% | 0−100%0.0% | 0−100%0.0% | 0.4−15.8%1.6% | 0.5−9.0%0.5% | 0.5−14.0%0.4% | 0.5−8.5%0.4% | 0.5−1.0%0.5% | 0.5+29.4%0.4% | 0.6—0.4% | 0.6—0.4% | 0.5r0.6—0.3% | 0.4—0.2% | |
| Goodwill | — | — | — | — | — | 0—0.0% | — | — | 0−100%0.0% | 0—0.0% | 0—0.0% | 17—10.8% | 18—10.5% | |
| Other intangible assets | 0—0.0% | 0−100%0.0% | 0−100%0.0% | 0−100%0.0% | 68+12.9%72.5% | 68+5.0%61.6% | 68+9.3%57.6% | 62+0.2%58.2% | 60−5.7%52.5% | 65—51.0% | 62—45.8% | 62—39.1% | 64—37.9% | |
| Investments in associates | — | — | 0.10.0%0.1% | 0.10.0%0.3% | 0.10.0%0.1% | 0.10.0%0.1% | 0.10.0%0.1% | 0.1—0.1% | 0.10.0%0.1% | 0.1—0.1% | 0.1—0.1% | — | 0.1—0.0% | |
| Total assets | 106—100% | 106−3.1%100% | 124+5.8%100% | 27−75.1%100% | 94−18.3%100% | 110−13.1%100% | 117−13.1%100% | 107−32.8%100% | 114−31.8%100% | 127—100% | 135—100% | 159—100% | 168—100% | |
| Accounts payable | 1.5—1.4% | 1.5−57.3%1.4% | 4.6+164%3.7% | 5.4+79.3%20.3% | 2.2−23.4%2.4% | 3.4+110%3.1% | 1.8−26.9%1.5% | 3.0+45.3%2.8% | 2.9+42.8%2.5% | 1.6—1.3% | 2.4—1.8% | 2.1—1.3% | 2.0—1.2% | |
| Debt due within a year | 0—0.0% | 0−100%0.0% | 0—0.0% | 0—0.0% | 18—19.3% | 18—15.9% | — | — | 0—0.0% | — | — | — | — | |
| Current liabilities | 7.2—6.8% | 7.2−72.3%6.8% | 8.5+13.8%6.9% | 8.8+4.9%32.9% | 43+494%46.2% | 26+380%23.7% | 7.5−27.7%6.4% | 8.4−15.1%7.8% | 7.3−24.0%6.4% | 5.4—4.3% | 10—7.7% | 9.8—6.2% | 9.6—5.7% | |
| Lease liabilities (non-current) | 0—0.0% | 0−100%0.0% | 0−100%0.0% | 0.3−23.5%1.1% | 0.3−16.2%0.4% | 0.4−20.2%0.3% | 0.4−14.6%0.3% | 0.4−2.8%0.4% | 0.4+22.7%0.3% | 0.5—0.4% | 0.5—0.3% | 0.4r0.5—0.2% | 0.3—0.2% | |
| Total liabilities | 28—26.6% | 28−73.9%26.6% | 16−85.3%12.5% | 11−87.6%41.1% | 129+53.2%138% | 109+33.4%99.0% | 105+20.0%90.0% | 89+4.0%82.6% | 84+1.8%73.7% | 82—64.5% | 88—65.2% | 85—53.4% | 83—49.3% | |
| Retained earnings | −528—−496% | −528—−496% | −500—−403% | −425—−1595% | −460—−492% | −421—−383% | −408—−348% | −392—−366% | −376—−329% | −364—−288% | −359—−266% | −331—−208% | −320—−190% | |
| Shareholders' equity | −66—−61.7% | −66−6304%−61.7% | −35−401%−28.5% | 16−15.7%58.9% | −36−218%−38.2% | 1.1−97.6%1.0% | 12−75.0%10.0% | 19−75.0%17.4% | 30−64.6%26.3% | 45—35.5% | 47—34.8% | 74—46.6% | 85—50.7% | |
| Total liabilities and equity | 106—100% | 106−3.1%100% | 124+5.8%100% | 27−75.1%100% | 94−18.3%100% | 110−13.1%100% | 117−13.1%100% | 107−32.8%100% | 114−31.8%100% | 127—100% | 135—100% | 159—100% | 168—100% | |
| Shares outstanding | 1.0—— | 1.0−98.1%— | 1.0−98.1%— | 14−68.7%— | 0.3r56−99.4%— | 54+25.9%— | 54+23.9%— | 44+2.0%— | 44+2.4%— | 43—— | 43—— | 43—— | 43—— | |
| Cash-flow statement | ||||||||||||||
| Depreciation and amortization | 0.1+10.1%— | 0.0*−58.3%— | 0.0*+17.1%— | 0.0+12.5%— | 0.0*+144%— | 0.0*−58.1%— | 0.0*−20.5%— | 0.0−20.0%— | 0.0*−94.7%— | 0.1*—— | 0.0*—— | 0.0—— | 0.3*—— | |
| Share-based compensation | 16+222%— | 1.6+30.3%— | 12+850%— | 1.3−7.2%— | 1.2*+5.9%— | 1.3+11.7%— | 1.3+4.1%— | 1.4+8.8%— | 1.1*+3.6%— | 1.1—— | 1.2—— | 1.3—— | 1.1*—— | |
| Cash from operating activities | −47—— | −9.8*—— | −19*—— | −7.6—— | −10*—— | −9.9*—— | −11*—— | −9.6—— | −7.6*—— | −7.3*—— | −8.7*—— | −8.4—— | −6.1*—— | |
| Capital expenditure | −0.1—— | −0.1*—— | 0*—— | 0—— | −0.0*—— | −0.1*—— | −0.1*—— | −0.1—— | −0.1*—— | −0.0*—— | −0.0*—— | −0.0—— | −0.0*—— | |
| Acquisitions, net of cash acquired | — | 0*—— | — | — | — | 0*—— | — | — | — | — | — | — | — | |
| Cash from investing activities | −40−253%— | −68*—— | 8.0*+32.5%— | 12+10.1%— | 8.1*−25.7%— | −1.8*−125%— | 6.0*—— | 11+22.3%— | 11*+102%— | 7.1*—— | −5.0*—— | 8.9—— | 5.4*—— | |
| Shares issued | — | — | — | — | — | — | — | — | — | — | — | — | 0*—— | |
| Cash from financing activities | 120+658%— | −0.0*−101%— | 109*+656%— | 9.4+10754%— | 2.0*—— | 1.4*—— | 14*+41077%— | 0.1−54.2%— | 0*−100%— | −5.0*—— | 0.0*—— | 0.2—— | 0.1*—— | |
| Exchange-rate effect on cash | −0.5−227%— | 1.5*—— | −0.2*−1305%— | −1.5−935%— | −0.3*−220%— | −0.0*—— | 0.0*—— | 0.2−43.5%— | 0.2*—— | −0.1*—— | −0.2*—— | 0.3—— | −0.2*—— | |
| Change in cash | 33+783%— | −76*—— | 98*+980%— | 12+692%— | −0.6*−118%— | −10*—— | 9.1*—— | 1.6+46.9%— | 3.5*—— | −5.2*—— | −14*—— | 1.1—— | −0.9*—— | |
| Report | Worked out | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
Executive pay at IRulya Therapeutics Inc.#
From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.
| Fiscal year | CEO total pay | Actually paid | Other executives, average | $100 invested |
|---|---|---|---|---|
| 2025Dr. Thye | $2.4 M | $3.9 M | $1.2 M | $526 |
| 2024Dr. Thye | $2.7 M | $3.4 M | $1.1 M | $293 |
| 2023Dr. Thye | $1.3 M | $2.5 M | $1.0 M | $165 |
Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025
Events at IRulya Therapeutics Inc.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
Delisting notice 2 · Acquisition or sale completed 2 · Directors and officers 9 · Material agreement 3 · Agreement ended 1 · New debt 1 · Unregistered share sale 2 · Shareholder rights changed 3 · Bylaws or fiscal year changed 5 · Shareholder vote 3 · Results announced 4
| Filed | What happened | Filing |
|---|---|---|
| Directors and officersBylaws or fiscal year changed | 8-K | |
| Directors and officersBylaws or fiscal year changedShareholder vote | 8-K | |
| Directors and officers | 8-K | |
| Acquisition or sale completedDirectors and officers | 8-K | |
| Delisting notice | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Shareholder rights changedBylaws or fiscal year changed | 8-K | |
| Shareholder rights changed | 8-K/A | |
| Shareholder vote | 8-K | |
| Acquisition or sale completedDirectors and officersMaterial agreementUnregistered share saleBylaws or fiscal year changed | 8-K | |
| Directors and officers | 8-K | |
| Shareholder rights changedBylaws or fiscal year changed | 8-K | |
| Agreement ended | 8-K | |
| Delisting notice | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Material agreementNew debt | 8-K | |
| Results announced | 8-K | |
| Material agreementUnregistered share sale | 8-K | |
| Shareholder vote | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Oct 9, 2026
Acquisitions and funding#
1 acquisitions · 2 private funding rounds before listing
Businesses it acquired
| Acquired | Acquisition date | Completion | Price | Stake | Source |
|---|---|---|---|---|---|
| Ery Del | Oct 2023 | Oct 2023 | — | — | Annual report |
Private share sales · funding history
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| May 2026 | $115 M | Private placement after listing | $50 to $250 million | 27 | equity, options | SEC |
| Jun 2025 | $11 M | Private placement after listing | $10 to $50 million | 15 | equity, options | SEC |
| May 2018 | $84 M | No. 2 | $50 to $250 million | 36 | equity | SEC |
| Dec 2015 | $8 M | No. 1 | $2 to $10 million | 13 | equity | SEC |
Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.
From US state WARN notices and SEC 8-K restructuring filings, newest first.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023 | · | · | · | · | · | · | · | · | · | · | · | · | — |
| 2022 | · | · | · | · | · | · | · | · | · | · | · | · | — |
| Announced | People | Kind | Where | Source |
|---|---|---|---|---|
| 47% of workforce | Restructuring planSEC 8-K | “Under the Plan, the Company is reducing headcount by approximately 47% through a reduction in its workforce.” | Filing | |
| 36% of workforce | Restructuring planSEC 8-K | “The Company is further reducing headcount by 36%, bringing the total reduction to 67% from the January 2022 headcount levels.” | Filing | |
| 53% of workforce | Restructuring planSEC 8-K | “Under the Plan, the Company is reducing headcount by approximately 53% through a reduction in its workforce.” | Filing |
Source: State WARN notices and SEC 8-K item 2.05
How IRulya Therapeutics Inc. compares in Biotechnology
- Market cap$343 M · higher than 53% of 726
- FCF yield-12.2% · higher than 53% of 449
Peer comparison · Biotechnology
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| IRulya Therapeutics Inc.🇺🇸 | $343 M | — | — | — |
| Novo Nordisk A/S🇩🇰 | $203.2 B | 13.1× | 33.1% | +10.8% |
| Vertex Pharmaceuticals Incorporated🇺🇸 | $134.3 B | 33.8× | 30.7% | +8.9% |
| Moderna, Inc.🇺🇸 | $90.1 B | — | -110.5% | -39.9% |
| Regeneron Pharmaceuticals, Inc.🇺🇸 | $84.1 B | 17.5× | 28.5% | +1.0% |
| Argenx SE🇳🇱 | $52.8 B | 40.9× | 31.1% | +89.9% |
| CSL Limited🇦🇺 | $51.6 B | — | -16.4% | — |
| Samsung Biologics Co., Ltd.🇰🇷 | $51.5 B | 40.5× | 39.2% | — |
| UCB SA🇧🇪 | $48.6 B | 26.3× | 20.1% | +31.1% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Regenxbio Inc.$513 M
- Pharmicell Co., Ltd.$514 M
- Pulike Biological Engineering, Inc.$524 M
- Contineum Therapeutics, Inc.$534 M
- Entera Bio Ltd.$543 M
- Arvinas, Inc.$544 M
Sources and freshness
- Market cap:
- Oct 30, 2026
- Annual results:
- For year ending December-2025
- Balance sheet:
- As of December-2025
- Employees:
- As on 2021
- Profile updated:
- Nov 20, 2026
Figures from Market data, SEC filing, value.today research; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at IRulya Therapeutics Inc.? Verify and update this profile — free
Show IRulya Therapeutics Inc.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.